Photo for representation only. Source: iStock.
Zurich/Geneva, October 16
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology.
"It's a reliable result, don't let anybody tell you otherwise, because they'll try to," Richard Peto, an independent statistician hired by the WHO to evaluate its Solidarity trial, told reporters, adding that any benefit of remdesivir may be due to chance.
Gilead has questioned the findings that concluded remdesivir does not help patients who have been admitted to hospital, saying the "emerging (WHO) data appears inconsistent". Gilead was given data from the United Nations health agency's trial 10 days ago, to give it an opportunity to react. — Reuters
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
1 soldier killed, 4 injured after terrorists ambush IAF convoy in J-K's Poonch
Reinforcements from army and police have been rushed; massiv...
Karnataka sex scandal: JD(S) MLA HD Revanna taken into custody by SIT in kidnapping case
The former minister was picked up from his father and JD(S) ...
Lok Sabha election: Will Prajwal Revanna controversy affect BJP prospects in Karnataka
The BJP leadership is ‘worried to some extent’, say sources;...
Here is all about 3 Punjabi youth held in Canada for Khalistani activist Hardeep Nijjar’s killing
Karan Brar belongs to Kotkapura and his father Mandeep Singh...
Lovely Professional University-Phagwara student from Noida, 3 others sustain bullet injuries in clash between two groups
Incident occurred at university's Law Gate in wee hours of S...
